Innovation in Lyme Diagnostics
LymeX Phase 4
The LymeX Diagnostics Prize is a $10+ million competition to accelerate the development of Lyme disease diagnostics.
Phase 4 includes seven teams with a goal of completing regulatory submissions to the FDA. StudioDx is supporting Phase 4 teams via our membership program, providing access to clinical validation support and our team of regulatory experts.
Our Lab-to-Market program with the Phase 4 teams will be scaled to support additional companies, bringing open source tools and know-how to the broader diagnostics space, enabling preventive products and therapies to reach the market fast.
LymeX
The Lyme Innovation Accelerator (Lyme-X) is a partnership between the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation. StudioDx has supported innovation in Lyme diagnostics since its founding and is now a collaborator of the LymeX program.
StudioDx’s mission of faster, cheaper diagnostics fits perfectly with HHS and Lyme-X’s goals for “identifying, developing, and implementing advancements in Lyme disease care — including next-generation diagnostics.”
Moving Lyme Diagnostics Forward
Our founders discuss their work with LymeX members and the difficulties and opportunities to achieving better, more actionable Lyme diagnostics.
